1. Home
  2. IBCP vs OMER Comparison

IBCP vs OMER Comparison

Compare IBCP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Independent Bank Corporation

IBCP

Independent Bank Corporation

HOLD

Current Price

$35.46

Market Cap

703.3M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$8.82

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBCP
OMER
Founded
1864
1994
Country
United States
United States
Employees
270
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
703.3M
772.8M
IPO Year
2010
2008

Fundamental Metrics

Financial Performance
Metric
IBCP
OMER
Price
$35.46
$8.82
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$37.00
$32.50
AVG Volume (30 Days)
100.5K
1.7M
Earning Date
04-23-2026
05-14-2026
Dividend Yield
3.35%
N/A
EPS Growth
3.48
98.15
EPS
0.81
0.62
Revenue
$32,075,000.00
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$8.98
$233.22
P/E Ratio
$43.60
$16.42
Revenue Growth
0.30
N/A
52 Week Low
$29.63
$2.95
52 Week High
$37.39
$17.65

Technical Indicators

Market Signals
Indicator
IBCP
OMER
Relative Strength Index (RSI) 61.96 24.11
Support Level $32.22 $8.27
Resistance Level $35.54 $12.06
Average True Range (ATR) 0.69 0.77
MACD 0.17 -0.12
Stochastic Oscillator 84.29 40.39

Price Performance

Historical Comparison
IBCP
OMER

About IBCP Independent Bank Corporation

Independent Bank Corp. operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers. The firm's principal markets are the rural and suburban communities across Lower Michigan. The firm generates the majority of its revenue from Interest and fees on loans.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: